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Abstract
Nicotine dependence as a result of smoking is a chronically relapsing disorder with detrimental effects . However, fortunately for 
smokers, an armamentarium of smoking cessation aids is available in the forms of nicotine replacement therapy (NRT), non-nico-
tinic drugs (namely varenicline and bupropion), and the novel nicotine vaccines, each with their own mode of action to moderate 
nicotine addiction . This paper analyzes the mechanism of action associated with nicotine addiction and the various methods of 
combat, or at the very least, attenuation of the addiction .
Effective Treatments for Nicotine Addiction
Chaya Shor
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Introduction
Though incognito, nicotine addiction has been proven to 
be the true killer in the seemingly innocent activity of 
smoking, for it reinforces the desire to smoke. To pre-
vent the myriad adverse effects of smoking, smokers 
need to work very hard to break nicotine addiction 
through smoking cessation. Nonetheless, many smokers 
find themselves dealing with many ups and downs in the 
quitting process. It comes as no surprise that nicotine 
addiction is therefore identified as a “chronic condition” 
by The US Clinical Practice Guideline, as many smokers 
need to make several attempts before they 
successfully wean themselves off completely 
(Fagerström & Hughes, 2008). Smoking is the 
second most expensive chronic health condi-
tion in the United States, with an estimated 
economic cost of 300 billion dollars per year 
(Jordan & Xi, 2018). Yet, stopping smoking can 
reverse the biological and economical dam-
age caused by smoking (Benowitz, 2010).
Understandably, 70% of smokers admit that 
they would like to quit. Every year, about 40% 
quit for at least a day. However, due to the extreme dif-
ficulty to abstain, about 45 million Americans currently 
smoke tobacco. Moreover, the 80% who attempt to quit 
on their own return to smoking within a month. Each 
year, only 3% of smokers quit successfully and remain ab-
stinent one year later, highlighting the critical need for 
effective long-term smoking treatments (Benowitz, 2010).
Methods
This comprehensive review is based on critical analy-
ses of literature obtained using various databases avail-
able through The Touro College Library online, such 
as PubMed and ProQuest. The National Center for 
Biotechnology (NCBI) website was also useful in 
provid ing additional source material.
Nicotine Addiction
Cigarette smoking is  a  major cause of death, cardio-
vascular disease, and pulmonary disease. It also pres-
ents the risk for various infections, osteoporosis, repro-
ductive disorders, adverse postoperative events, delayed 
wound healing, duodenal and gastric ulcers, and diabetes 
(Benowitz, 2010). Although nicotine itself plays a minor 
role, if any, in causing smoking-induced diseases, the addic-
tion to nicotine, which leads to sustained smoking use, is 
the proximate cause of these diseases (Onor et al., 2017).
Nicotine (C10H14N2) is a plant alkaloid found in the 
tobacco plant (Onor et al., 2017) that consists of a pyri-
dine and pyrrolidine ring, each one possessing a tertiary 
amine (Escobar-Chávez et al., 2011). The pKa of the pyr-
idine nitrogen is 3.04 and the pKa of the pyrrolidine ni-
trogen is 7.84 under standard conditions. Based on these 
characteristics, nicotine’s distribution exists among three 
forms, depending on the pH of the solution. An increase 
in acidity of solution increases the fraction of protonated 
molecules; conversely, a more basic environment increas-
es the fraction of the unprotonated, or free base, form 
(Figure 1). Although all forms of nicotine are highly soluble 
in water and can easily dissolve in lung fluids and blood, 
the unprotonated nicotine smoke particles are volatile, 
whereas the protonated form is not. Conventionally, a 
sample of particulate matter from cigarette smoke is not 
acidic enough to cause the protonated form to dominate. 
Thus, a higher percentage of unprotonated nicotine can 
rapidly cross biological lipid membranes and be deposited 
in the respiratory tract (Centers for Disease Control and 
Prevention, 2010). Nicotine begins to reach the brain ten 
seconds after inhalation and its concentration continues 
to increase gradually (Dani et al, 2011).
Blood concentrations of nicotine rise rapidly and peak 
at the completion of smoking. The rapid absorption of 
nicotine is attributed to the broad surface area of the 
alveoli and small airways. This rapid rise allows the smok-
er to titrate and manipulate the level of nicotine during 
smoking, which makes smoking the most reinforcing and 
dependence-producing form of nicotine administration 
(Benowitz et al., 2009).




Essentially, pharmacologic feedback, learned factors, ge-
netics, and environmental factors (including tobacco prod-
uct design and marketing, stress, smoking cues, or peers 
who smoke) contribute to nicotine addiction. Other fac-
tors include sex, age, mental illness, and substance abuse. 
Although each of these features contributes, the one that 
will be discussed with percipience is the pharmacological 
interplay with nicotine addiction (Benowitz et al., 2009).
The pharmacological basis for nicotine use is enhance-
ment of mood and augmentation of mental and physical 
functions. Inhalation of smoke from a cigarette allows 
nicotine from the smoke particles to diffuse through the 
lungs, where it is rapidly absorbed into the pulmonary 
venous circulation. From there, it moves quickly to the 
left ventricle of the heart and to the systemic arterial cir-
culation and brain. Based on human autopsy samples from 
smokers, the liver, kidney, spleen, and lung have the highest 
affinity for nicotine (Benowitz et al., 2009). Subsequently, 
the nicotine enters arterial circulation to be moved from 
the lungs to the brain with high affinity, where it binds to 
nicotinic acetylcholine receptors (nAchRs), ligand-gated 
ion channels that normally bind a neurotransmitter ace-
tylcholine (Benowitz, 2010).
NAchRs are pentameric structures consisting of a com-
bination of five different subunits, including nine α sub-
units (α2 through α10) and three β subunits (β2 through 
β4), resulting in at least 12 unique nAchR subtypes that 
have been identified thus far. The α4β2 receptor, though, 
is the prime mediator of nicotine dependence. As seen 
in positron emission tomography studies in humans, 
smoking a full nicotine cigarette nearly saturated α4β2 
receptor occupancy. In fact, when disruption of the β2 
subunit gene was tested in mice, the behavioral effects of 
nicotine were eliminated. Similarly, the α4 subunit is an 
important determinant of sensitivity to nicotine. This was 
confirmed when a mutation affecting a single nucleotide 
in the pore-forming region of the receptor gene in mice 
made it hypersensitive to the effects of nicotine. These 
observations strongly implicate α4β2 nAchRs in nicotine 
addiction and illustrate the α4β2 receptor as a potentially 
attractive medicinal target for treatment of the addiction 
(Jordan & Xi, 2018).
The smoker craves nicotine to propagate dopamine 
overflow in the pleasure-seeking areas of the brain. The 
α4β2 are located on the dopamine (DA) cells of the me-
solimbic system. The system is comprised of projections 
from DA neurons in the ventral tegmental area (VTA) 
to the nucleus accumbens (NAc), the part of the brain 
responsible for reward, pleasure, laughter, aggression, and 
fear, and the prefrontal cortex. Nicotine binding to α4β2 
receptors on VTA DA cells increases neuronal excitability 
and neurotransmitter release, opening the ligand-gated 
ion channel, and allowing Ca2+ and Na+ to cascade intra-
cellularly, which stimulates DA release to NAc (Figure 2). 
This is the underlying effect of nicotine’s reward cascade, 
as dopamine serves as a pleasure signal and mood modu-
lator and is critical for reinforcing nicotinic effects (Jordan 
& Xi, 2018).
When studied under laboratory conditions, nicotine 
elicits classic addictive responses (Dani et al, 2011). In 
order to reap the rewarding feeling associated with nico-
tine and avoid withdrawal symptoms, smokers must main-
tain a certain nicotine level. Repetitive exposure to nico-
tine leads to neuroadaptation and tolerance to nicotine’s 
effects, and accumulation of nicotine in the body leads to 
a more substantial withdrawal reaction if cessation is at-
tempted. Common withdrawal symptoms include anxiety, 
difficulty concentrating, and irritability, all of which can 
last for days, weeks, or longer (Onor et al., 2017).
As neuroadaptation occurs, the number of binding 
sites on the nicotinic cholinergic receptors in the brain 
increases. This causes desensitization, wherein a ligand-in-
duced closure and unresponsiveness of the receptor 
occurs due to the profusion of ligand infiltration. Thus, 
the feelings of craving and withdrawal are exacerbated 
during periods of abstinence due to the mitigated lev-
els of dopamine and other neurotransmitters. However, 
during a smoking period, binding to the α4β2 cholinergic 
receptors alleviates the need for nicotine. To circumvent 
withdrawal symptoms, smokers will sustain sufficient lev-
els of plasma nicotine (Benowitz, 2010). 
It comes as no surprise that nicotine withdrawal is 
extremely taxing on the smoker. Such repercussions are 
powerful incentives to take up smoking again (Benowitz, 
2010). Fortunately for smokers, there is an expansive mar-
ket of nicotine treatments that promote smoking cessa-
tion, some of them in the form of nicotine replacement 
therapy (NRT), non-nicotinic drugs such as bupropion and 
varenicline, and finally, the emergence of nicotine vaccines.
Figure 2 . Schematic diagram of the mesolimbic DA projection 
pathway in the human brain . Nicotine activates a4b2 nAChRs 
located on DA neurons located in the VTA, as illustrated (Xi, 2010) .
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Nicotine Replacement Therapy (NRT)
Nicotine’s rapid rate of absorption and entry to the brain 
are key factors responsible for the high abuse potential. 
Unlike cigarettes, nicotine replacement therapy (NRT) 
products such as gums, inhalers, and transdermal patch-
es can help relieve the physical withdrawal symptoms 
by providing gradual increments of nicotine without the 
damaging chemicals found in cigarette smoke (Jordan & 
Xi, 2018). The gradual distribution of nicotine results in 
low abuse liability of NRTs. Although NRT doesn’t com-
pletely eliminate withdrawal symptoms since it does not 
provide rapid and high levels of nicotine, NRT may pro-
vide a coping mechanism, making cigarettes less enticing 
to smoke (Molyneux, 2004) and increasing the rate of 
quitting by 50 to 70% (Stead et al., 2012). NRTs are well 
tolerated and have minimal adverse effects, but are most 
effective when used in conjunction with intense behavior-
al support (Molyneux, 2004).
In 1984, transmucosally delivered nicotine polacrilex, or 
nicotine gum, was introduced as the first effective NRT to 
serve as a smoking cessation aid, as approved by the US 
Food and Drug Administration (FDA). It is not chewed like 
ordinary confectionary gum, as it must be intermittently 
chewed and held in the mouth for over 30 minutes to 
achieve optimal release of nicotine. The absolute dose of 
nicotine absorbed systemically is much less than the nico-
tine content of the gum, in part because considerable nic-
otine is swallowed with first-pass metabolism (Benowitz et 
al., 2009), where it gets metabolized in a specific location 
other than the location of interest, reducing the concen-
tration that enters systemic circulation (Herman &Santos, 
2019). The dosage is slowly decreased until it is no longer 
required (Wadgave & Nagesh, 2016).
To satisfy the behavioral hand-to-mouth ritual of smok-
ing, the nicotine oral inhaler was introduced to the NRT 
market. Contrary to its label, the inhaler is mainly delivered 
to the oral cavity, esophagus, and stomach, and negligibly to 
the lungs. Because absorption is mainly through the oral 
mucosa, a slow absorption rate of nicotine is achieved, akin 
to that of nicotine gum (Wadgave & Nagesh, 2016).
In a parallel fashion, nicotine patches deliver nicotine 
at a relatively steady rate when applied to and readily 
absorbed through the skin. In fact, the patch is the form 
that delivers nicotine at the slowest rate when compared 
to the other forms of NRT. A chief advantage of nico-
tine patches is the simplicity of user compliance, since 
the patch can be placed on the skin in the morning and 
worn for the duration of the day. The patches are available 
in a range of doses, allowing users to gradually decrease 
their nicotine intake over the span of several weeks or 
longer to ensure a proper adjustment to lower nicotine 
levels until they can attain a nicotine-free state. The rate 
of nicotine release is controlled by the permeability of 
the skin, rate of diffusion through a polymer matrix, and 
rate of passage through membranes in the various patch-
es on the market. In all cases, there is an initial lag time of 
1 hour before nicotine enters the bloodstream, followed 
by continued systemic absorption once the patch is re-
moved, the latter due to the vestiges of nicotine in the 
skin (Benowitz et al., 2009). Current evidence supports 
the safety of long-term use of nicotine patches for nico-
tine treatment (Wadgave & Nagesh, 2016).
Non-Nicotinic Drugs 
Bupropion (Wellbutrin)
The first non-nicotine drug to treat nicotine addiction 
was introduced in 1997. Bupropion (amfebutamone), 
marketed as Wellbutrin and Zyban among others (Fava, 
et al., 2005), an amphetamine-based drug, is a reuptake 
inhibitor of dopamine into neuronal synaptic vesicles 
and a blocker of nicotine’s activation of several neuro-
nal nAChRs. Bupropion undergoes metabolic transfor-
mation to an active metabolite, 4-hydroxybuproprion, 
through hepatic cytochrome CYP2B6, (Foley et al., 2006). 
Bupropion’s structure is akin to nicotine, rendering it a 
compatible competitor (Figure 3). Originally developed 
as an antidepressant, a systematic review of 44 clinical 
trials found that sole therapy with bupropion significantly 
increased long-term (≥6 months) smoking abstinence, af-
firming its efficacy as an anti-smoking agent (Onor et al., 
2017). It should be noted that the antismoking effect does 
not seem to correlate with its antidepressant effect, as 
bupropion is equally as effective for smoking cessation for 
individuals with and without depression (Roddy, 2004).
Figure 3 . The chemical structures of bupropion (left) and nicotine 
(right) (National Center for Biotechnology Information) .
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When nicotine infiltrates the blood and crosses the 
blood brain barrier, there is a release of dopamine into 
the synaptic cleft of neurons in the dopaminergic path-
ways. After nicotine levels subside, dopamine reuptake 
into the axon terminal vesicles occurs. Bupropion is 
thought to inhibit this dopamine reuptake. In vivo studies 
have also shown that bupropion antagonizes the effects 
of nicotine at the postsynaptic acetylcholine nicotinic re-
ceptor (Wilkes, 2008). During withdrawal, bupropion may 
attenuate symptoms by mimicking the effects of nicotine 
on dopamine (Warner & Shoaib, 2005). These effects may 
explain how bupropion inhibits the reinforcing effects 
of nicotine, though it is still unclear whether bupropion 
offers any long-term relapse prevention following termi-
nation of treatment. Nonetheless, both pragmatic and ob-
servational trials of bupropion have shown that approx-
imately 1 in 5 smokers will successfully remain abstinent 
for at least a year post-treatment (Wilkes, 2008).
Varenicline (CHANTIX)
Cytisine is a naturally occurring insecticide found in the 
leaves and seeds of Cytisus laburnum (golden rain tree). 
During World War II, soldiers smoked leaves of this tree 
in lieu of tobacco. Both varenicline and cytisine target 
the α4β2 receptor, where varenicline was developed to 
improve binding to the receptor to enhance efficacy of 
smoking cessation. However, the cytisine structure did 
not lead to a viable drug candidate. In due course, a series 
of efforts based on analgesic bicyclic benzazepines, one of 
which was unveiled as a potent α4β2 nAchR antagonist, 
served as a novel template that led to the development 
of varenicline, branded as CHANTIX. FDA approval was 
based on randomized clinical trials conducted in 3659 
subjects in the United States. The subjects, all of whom 
were chronic smokers, averaged 43 years of age and re-
ported smoking an average of 21 cigarettes per day for 
the previous 25 years. The primary outcome measured 
abstinence from smoking, which came in at a 44% rate, 
a significant improvement over bupropion (30%) and 
placebo (18%). Secondary outcomes, such as the urge to 
smoke and withdrawal symptoms, were likewise improved 
in varenicline-treated subjects over placebo (Jordan & Xi, 
2018). In 2006, varenicline received FDA approval, and it 
was highly touted as an aid to quit smoking (Fagerström 
& Hughes, 2008).
Like bupropion, varenicline has a somewhat paral-
lel configuration to its nicotine competitor in order to 
operate as an appropriate replacement. In fact, in vitro 
binding assays indicate that varenicline’s affinity for the 
α4β2 receptor (Ki = .15 nM) is higher than that of nic-
otine (Ki = 1.6 nM) and cytisine (Ki = 0.23 nM) (Jordan 
& Xi, 2018). Varenicline has the following chemical name: 
7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino[2,3- h]
[3]benzazepine, (2R,3R)-2,3-dihydroxybutanedioate (1:1) 
(Figure 4). Varenicline has a molecular weight of 361.35 
Daltons and is highly soluble in water (Pfizer Labs, 2016).
With varenicline, dopamine is still released, but less so 
than with nicotine. Since the α4β2 had been identified to 
have the highest sensitivity to nicotine, it had become a 
potential target for the smoking cessation drug. Varenicline 
was developed to have a high affinity for the α4β2 neu-
ronal nicotinic acetylcholine receptors in the mesolimbic 
dopamine system and stimulate receptor-mediated activity, 
but at a significantly lower level than nicotine. Varenicline’s 
highly selective nature ensures that it will bind more po-
tently to α4β2 receptors than to other common nicotinic 
or non-nicotinic receptors (Pfizer Labs, 2016).
As a result of being a partial agonist, varenicline displays 
both agonist and antagonist effects. Partial agonists have 
been reviewed thoroughly as a method of attenuating 
nicotine addiction. Partial agonists bind to nAchRs but 
do not elicit the maximum response of a full agonist, and 
instead depend on receptor occupancy by other ligands. 
For instance, in the presence of a full agonist like nicotine, 
a partial agonist would behave as an antagonist by occupy-
ing the receptor site, thereby minimizing nicotine’s effects 
at the receptor. However, in the absence of nicotine, a 
partial agonist would behave as an agonist by mitigating 
nicotine withdrawal symptoms through triggering a de-
gree of dopamine release (Jordan & Xi, 2018).
Given that continuous abstinence rates across studies 
remain low (18-30% with varenicline; 4-10% with place-
bo), novel and more effective treatments may be required. 
However, since FDA approval in 2006, incoming reports 
have been continuing to demonstrate varenicline’s effi-
cacy for smoking cessation over the alternatives. For 
example, in a randomized trial involving 376 participants 
over the span of 52 weeks, varenicline resulted in higher 
abstinence rates from smoking (55.9%) when compared 
to transdermal NRT (43.2%), highlighting varenicline’s 
progress (Jordan & Xi, 2018).
Figure 4 . The chemical structures of nicotine (left), cytisine (middle), 
and varenicline (right) (Xi, 2010) .
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Nicotine Vaccines
With the advent of the novel nicotine vaccines, smokers 
have an alternative course of action through which they 
can quit smoking. Currently undergoing clinical trials, the 
goal of the vaccine is to generate antibodies that sequester 
nicotine in the blood and hinder the pharmacological ef-
fects by preventing access into the brain. Thus, the vaccine 
brims with potential for treatment of nicotine addiction 
and relapse prevention (Goniewicz & Delijewski, 2013).
Based on the assumption that a rapid increase in brain 
nicotine levels induces feelings of reward, preventing nic-
otine from entering the brain is an intriguing idea with 
precedent in other, similar treatments. Using antibodies 
to bind a drug and thus disabling it from crossing the 
blood-brain barrier was first tested in the realm of heroin 
addiction and extended to nicotine and cocaine addiction 
(Raupach et al., 2012).
Since nicotine is too small to elicit a response from the 
immune system, nicotine is not immunogenic. In order 
to elicit an immune response, nicotine or a structurally 
similar hapten needs to be paired with a larger carrier 
protein, thus producing a conjugate vaccine (Goniewicz 
& Delijewski, 2013). Vaccination administers an immu-
nogenic substrate that activates T and B cells, leading to 
the formation of specific antibodies within the individual, 
imprinting the response in immunological memory. By 
virtue of this mechanism, this approach has been shown 
to yield longer lasting protection (Raupach et al., 2012).
When nicotine enters the body, the vaccine causes 
it to bind to the nicotine-specific antibodies, forming a 
complex too large to cross the blood-brain barrier. Thus, 
there is no nicotine-induced cerebral stimulation for 
the smoker and the impression received by the smoker 
is comparable to smoking a cigarette without nicotine 
(Escobar-Chávez et al., 2011).
The success of this immunological strategy hinges on im-
munogenicity of the vaccine, affinity of antibodies, and spec-
ificity of antibodies (Raupach et al., 2012). Immunogenicity 
refers to the antibody serum concentration. A vaccine 
must elicit and maintain a high antibody serum concen-
tration throughout the period of interest in order to be 
maximally effective (Escobar-Chávez et al., 2011).
The primary measure of antibody affinity to the target 
drug can be measured by the binding equilibrium con-
stant, Ka. The Ka is defined by Ka = [NicAb]/[Nic][Ab]. 
[NicAb] represents the plasma volume concentration of 
bound nicotine-antibody complexes, and [Nic] and [Ab] 
denote the volume concentrations of unbound drug and 
unbound antibody, respectively. Hence, in order to cal-
culate the percentage of bound nicotine, data regarding 
the amount of antibody present in circulation must be 
obtained beforehand. The Ka should be high enough to 
bind to nicotine and low enough to allow for unbound 
nicotine release and elimination (Goniewicz & Delijewski, 
2013). However, extremely high affinity may be disadvan-
tageous, as saturation of all antibodies compromises ef-
ficacy for subsequent nicotine doses (Fahim et al., 2011).
Interestingly, the interaction of antibodies with nico-
tine is reversible and each antibody binds to and releas-
es nicotine many times, much like a juggler catches and 
releases multiple sticks many times. Thus, it is observed 
that the binding capacity of the antibodies for nicotine is 
far in excess than the expected stoichiometric calculation 
(Escobar-Chávez et al., 2011).
Specificity refers to the extent to which the elicited 
antibodies bind to nicotine in preference to other mol-
ecules (Raupach et al., 2012). Greater specificity reduces 
competition from other molecules, thus improving safe-
ty and minimizing the likelihood of adverse side effects 
(Escobar-Chávez et al., 2011). This has practical applica-
tions for the design of conjugate vaccines. For example, 
one recent study showed that using longer rather than 
shorter linkers, amino acid sequences used to separate 
multiple domains in a protein (Reddy Chichili et al., 2013), 
increases antibody selectivity to nicotine. Additionally, 
linker position influences specificity. Linkers that are dis-
tant from the prime sites of metabolism (i.e. attached to 
the 6- rather than 5- position of the pyridine ring) help 
enhance antibody selectivity (Raupach et al., 2012).
In order to maintain an ideal serum antibody concen-
tration, repeated administration of the nicotine-conjugate 
system in the form of the vaccine is required. The first 
vaccination administered causes a primary immune re-
sponse, comparable to when the organism had its initial 
encounter with an infectious antigen. Each subsequent 
administration acts as a “planned infection,” which uses 
memory about the antigens during the production of an-
tibodies. Therefore, a faster and more effective response 
to the subsequent vaccinations is anticipated (Goniewicz 
& Delijewski, 2013).
Due to the prolonged effect that nicotine vac-
cines provide, they have an advantage over the ex-
isting pharmacotherapies (Shen et al., 2012, as cited 
in Goniewicz & Delijewski, 2013) and are a critical 
addition to the pharmacological smoking cessation 
aids. The relapse rate is minimal since only bimonth-
ly booster shots are required to achieve a high level 
of antibodies. Thus, patient adherence to the neces-
sary protocol can significantly improve. Nevertheless, 
early clinical trials have casted some doubts in that 
many patients may not elicit a sufficient antibody re-
sponse. To circumvent this issue, novel carriers and/
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or adjuvants with immunogenic properties can be 
introduced to stimulate a more potent immune re-
sponse (Cerny et al., 2009, as cited in Goniewicz & 
Delijewski, 2013).
For those who attain high levels of antibodies, vacci-
nation has been shown to be effective in achieving and 
maintaining abstinence (Goniewicz & Delijewski, 2013). 
Vaccines against nicotine are at an advanced stage of 
clinical trials but have not yet been approved for treat-
ment of individuals (Escobar-Chávez et al., 2011). Future 
strategies for enhanced specificity that the vaccine can 
provide in conjunction with a high affinity to nicotine 
and increased antibody level offer an effective avenue for 
smoking-cessation (Goniewicz & Delijewski, 2013).
Discussion and Conclusion:
After reviewing the various smoking cessation techniques, 
it seems that a combination of a few would be the most 
viable option. The smoker can implement preliminary ar-
rangements with the use of NRT. NRT may be useful for 
those who want to attenuate the smoking habit but do 
not want to put a halt to it completely, known as quitting 
“cold turkey.” The choice of NRT can be guided by the 
patient’s preference, though it may be wise to have a first-
line agent in conjunction with NRT; however, healthcare 
professionals must learn the benefits and potential detri-
ments of different types of NRT before guiding patients in 
its potential use (Wadgave & Nagesh, 2016).
Smokers who find that they are unsuccessful with NRT 
can choose an alternative method. Although nicotine vac-
cines have an advantage over existing pharmacotherapies 
in that they have a prolonged effect and require sub-
stantially less cooperation from patients with bimonthly 
booster shots, data from clinical trials suggest that many 
patients may not produce sufficient antibody response 
(Goniewicz & Delijewski, 2013), suggesting that it may 
not be the most pragmatic approach.
Since nicotine addiction is primarily responsible in 
impeding smoking cessation and long-term abstinence, 
it seems that the most prudent option would be a mo-
dality that targets the activity at the α4β2 receptor, the 
prime mediator of nicotine dependence. Where bupro-
pion therapy aims to alleviate the withdrawal symptoms 
experienced during the transition state to a steady state 
of neurotransmitter activity, as does NRT, varenicline was 
developed to selectively target nicotine activity at the 
receptor that leads to the addiction, a seemingly more 
robust approach. Though varenicline presents a surfeit 
of undesirable side effects, some in the forms of nau-
sea, abnormal dreams, taste perversion, and headaches 
(Burke et al., 2016), these effects may prove manageable 
and worthwhile under a cost-benefit analysis. The strong 
rationale for targeting the α4β2 receptor with a par-
tial agonist, coupled with promising findings from clini-
cal studies, reinforce varenicline’s efficacy and safety as 
a reliable smoking cessation aid. Upregulation of these 
receptors and adaptation lead to the compulsive use of 
nicotine to maintain homeostasis, both of which render 
the α4β2 receptor an effective candidate for pharma-
cologic intervention. However, patients and providers 
should determine whether to use varenicline only after 
an assessment of the potential risks and benefits. The 
efficacy of varenicline can be improved in combination 
with NRT and bupropion, especially for smokers who are 
more heavily dependent on nicotine (Burke et al., 2016). 
Greater understanding of the exact mechanisms of these 
drugs, particularly bupropion, could lead to the devel-
opment of drugs that are more effective in promoting 
smoking abstinence (Warner & Shoaib, 2005).
All things considered, nota bene that relapse is often 
prominent in a patient’s attempt to quit smoking. The av-
erage patient will quit four or five times before reaching 
complete cessation, an important point to convey to pa-
tients to prevent disillusionment and hopelessness during 
recovery (Woody et al., 2008).
Essentially, the adverse health effects associated with 
cigarette smoking are numerous and continual efforts to 
reduce the prevalence of smoking are imperative (Onor 
et al., 2017). Nevertheless, due to futile attempts to quit, 
many smokers feel demoralized and incapable of taking 
action towards quitting. However, there are options 
available to the smoker. Whether in the form of NRT, 
non-nicotinic drugs (namely varenicline and bupropion), 
or the novel nicotine vaccines, nicotine addiction can be 
mitigated to aid the journey towards recovery.
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